Lilly wins Alimta Vitamin Regimen Patent Lawsuit against Apotex Inc
By Akshay Kedari  Date: 2019-12-31

Lilly wins Alimta Vitamin Regimen Patent Lawsuit against Apotex Inc

 

  • Ruling by the US District Court has concluded that Apotex Inc. would be infringing the Alimta vitamin regimen patent by launching its proposed products until the patent expiration of Lilly
     
  • The ruling would bar Apotex from marketing its alternative product until the patent expiration in May 2022

American pharmaceutical company, Eli Lilly and Company, announced that the U.S. District Court (Southern District of Indiana) decided in favor of the company in the Alimta Vitamin Regimen Patent Lawsuit. The court's verdict states that Apotex Inc, a competitor would be liable for infringement of Alimta vitamin regimen patent in the event the company selling generics of the drug prior to the expiration of the patent in May 2022. 

 

Apotex is a Canadian pharmaceutical corporation producing high-quality, affordable generic, as well as innovative pharmaceuticals, for patients across the globe. The ruling would prevent Apotex from marketing its generic form of the lung cancer drug Alimta. Lilly expects the competitor company to appeal the ruling. 

 

For the record, Alimta vitamin regimen is categorized as an antifolate drug, which is designed to bar cells from making DNA through the use of folic acid.

 

Lilly's senior vice president and general counsel, Michael J. Harrington was quoted saying that the company is pleased with the District Court's ruling finding the competitor’s proposition to be a case of infringement. Commenting further on the verdict Harrington stated that Lilly deserves intellectual property protection for its extensive research efforts concentrated on the discovery of the Alimta vitamin regimen. 

 

The Patent Trial and Appeal Board of the U.S. Patent and Trademark Office had also ruled in favor of the company in 2017. Similarly, the U.S. Court of Appeals for the Federal Circuit also upheld the validity of the patent in 2017. 

 

Source credit:

https://investor.lilly.com/news-releases/news-release-details/us-district-court-rules-favor-lilly-alimta-vitamin-regimen-0

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

RADCOM introduces automated assurance solution for 5G technology
RADCOM introduces automated assurance solution for 5G technology
By Akshay Kedari

5G technology has been in the headlines for quite a while. Next-generation technology has the potential to transform almost every sector across the world. However, as 5G becomes reality, it has become imperative for service providers to prevent degra...

Sprout to expand wellness solutions lineup by acquiring Vivametrica
Sprout to expand wellness solutions lineup by acquiring Vivametrica
By Akshay Kedari

Sprout, a Canadian company that focuses on delivering innovative solutions for workplace wellbeing, has recently announced the acquisition of predictive health data analytics firm, Vivametrica. According to reliable sources, Sprout plans to enhance t...

Uber halts decision to shift APAC headquarters from Singapore
Uber halts decision to shift APAC headquarters from Singapore
By Akshay Kedari

Uber Technologies Inc., the American ride-hailing giant, has reportedly halted the company’s decision to relocate its Asia Pacific headquarters from Singapore to Hong Kong until December 2022. Sources cite that the company’s decision was...

PCI Pharma extends global clinical supply-chain services in Europe
PCI Pharma extends global clinical supply-chain services in Europe
By Akshay Kedari

U.S. based biopharmaceutical and pharma outsourcing services company, PCI Pharma services has reportedly announced that it reached a noteworthy milestone through the development of COE (Clinical Center of Excellence) in Berlin. According to credible...

Dassault to use Proxem’s AI solution to advance 3DEXPERIENCE platform
Dassault to use Proxem’s AI solution to advance 3DEXPERIENCE platform
By Akshay Kedari

French software company, Dassault Systèmes has recently revealed plans to enhance its 3DEXPERIENCE platform’s collaborative data science abilities, allowing customers to take advantage of their data patrimony by taking part in new v...